A Randomized, Open-Label Study to Compare Progression-Free Survival in Patients With HER2 Positive Metastatic Breast Cancer Who Continue or Discontinue Herceptin [trastuzumab] in Combination With 2nd Line Chemotherapy, Having Progressed on 1st Line Chemotherapy in Combination With Herceptin.

Trial Profile

A Randomized, Open-Label Study to Compare Progression-Free Survival in Patients With HER2 Positive Metastatic Breast Cancer Who Continue or Discontinue Herceptin [trastuzumab] in Combination With 2nd Line Chemotherapy, Having Progressed on 1st Line Chemotherapy in Combination With Herceptin.

Completed
Phase of Trial: Phase III

Latest Information Update: 02 Dec 2014

At a glance

  • Drugs Trastuzumab (Primary) ; Antineoplastics
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Acronyms THOR
  • Sponsors Roche
  • Most Recent Events

    • 05 Dec 2011 Actual end date Nov 2011 added as reported by ClinicalTrials.gov.
    • 18 Apr 2011 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov.
    • 02 Mar 2010 Planned number of patients changed from 201 to 300 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top